Nadroparin calcium: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wik |
→top: infobox |
||
(36 intermediate revisions by 23 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
|||
⚫ | |||
| Watchedfields = changed |
|||
| IUPAC_name = |
|||
⚫ | |||
| image = |
|||
| IUPAC_name = (4S,6R)-6-[(2R,4R)-4,6-dihydroxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-3,4-dihydroxy-5-sulfonatooxyoxane-2-carboxylate |
|||
| image = File:Heparin General Structure V.1.svg |
|||
<!--Clinical data--> |
<!-- Clinical data --> |
||
| tradename = |
|||
| tradename = Fraxiparin(e), Fraxodi, others |
|||
| Drugs.com = {{drugs.com|international|nadroparin-calcium}} |
| Drugs.com = {{drugs.com|international|nadroparin-calcium}} |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = |
| legal_AU = S4 |
||
| legal_CA = Rx-only |
|||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_UK = |
|||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = [[Subcutaneous injection]] (except for [[haemodialysis]]) |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| protein_bound = |
| protein_bound = |
||
| metabolism = |
| metabolism = |
||
| elimination_half-life = |
| elimination_half-life = 3.7 hours (SC dose) |
||
| excretion = |
| excretion = clearance 21.4mL/min (+/- 7) |
||
⚫ | |||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|||
⚫ | |||
| |
| ChemSpiderID = none |
||
| CAS_number_Ref = {{cascite|changed|??}} |
|||
| CAS_number = 9005-49-6 |
|||
| UNII_Ref = {{fdacite|changed|FDA}} |
|||
| UNII = 1K5KDI46KZ |
|||
| ATC_prefix = B01 |
| ATC_prefix = B01 |
||
| ATC_suffix = AB06 |
| ATC_suffix = AB06 |
||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite| |
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
||
| DrugBank = |
| DrugBank = DB08813 |
||
| KEGG_Ref = {{keggcite|changed|kegg}} |
|||
| KEGG = D07510 |
|||
| ChEMBL_Ref = {{ebicite|changed|EBI}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
| molecular_weight_comment = g/mol |
|||
⚫ | |||
'''Nadroparin''' (trade names '''Fraxiparin[e]''', '''Fraxodi''', among others) is an anticoagulant belonging to a class of drugs called [[low molecular weight heparin]]s (LMWHs). Nadroparin was developed by [[Sanofi#Sanofi-Synthélabo|Sanofi-Synthélabo]]. |
|||
Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders ([[deep vein thrombosis]] and [[pulmonary embolism]]), and as treatment for [[deep vein thrombosis]]. It is also used to prevent clotting during [[hemodialysis]], and for treatment of [[unstable angina]] and non-Q wave [[myocardial infarction]].<ref name= "Aspri Canada">{{cite web|title=Fraxiparine PRODUCT MONOGRAPH (Canada)|url=http://www.aspripharma.com/pdf/Fraxiparine%20&%20Fraxi%20Forte%20PM_EN.pdf|website=Aspripharma.com|access-date=2 April 2019}}</ref> |
|||
⚫ | |||
⚫ | |||
For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the abdomen. It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO22nd">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
'''Nadroparin''' is a form of [[low molecular weight heparin]] sold by [[GSK]] under trademark '''Fraxiparine'''<ref>GSK PRODUCT MONOGRAPH; http://www.gsk.ca/english/docs-pdf/Fraxiparine_2011.pdf</ref>. |
|||
{{Reflist}} |
|||
⚫ | |||
{{reflist}} |
|||
==External links== |
==External links== |
||
* {{cite web|url=https://www.cancer.gov/publications/dictionaries/cancer-drug|title=NCI Drug Dictionary|date=2 February 2011|website=National Cancer Institute|access-date=2 April 2019}} |
|||
* http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128 |
|||
⚫ | * {{cite journal |vauthors=Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A |title=A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study |journal=Pharmacology |volume=78 |issue=3 |pages=136–43 |year=2006 |pmid=17057417 |doi=10.1159/000096484|s2cid=95878036 }} |
||
* http://www.mayoclinic.com/health/drug-information/DR600971 |
|||
⚫ | * {{cite journal | |
||
{{Antithrombotics}} |
{{Antithrombotics}} |
||
⚫ | |||
{{blood-drug-stub}} |
{{blood-drug-stub}} |
||
[[de:Nadroparin]] |
|||
[[pl:Nadroparyna]] |
|||
[[pt:Nadroparina cálcica]] |
|||
⚫ |